The U. S. sex reassignment hormone therapy market size is expected to reach USD 2.23 billion by 2030, growing at a CAGR of 4.05% during the forecast period. The growth is attributed to the increasing awareness about sex reassignment treatments and the rising patient pool seeking gender affirmation surgery and hormonal therapy. The number of such patients has increased fourfold in the past years.
Hormone therapy is a more economical solution than surgical procedures in gender-affirming care. While it offers a cost-effective solution, it necessitates long-term commitment and consistent usage to achieve desired outcomes. Moreover, in gender-affirming care, several drugs employed in the process are prescribed off-label in the U. S. Puberty blockers serve as the initial line of intervention for individuals seeking sex reassignment, followed by the administration of estrogen or testosterone depending on whether it is a male-to-female (MTF) or female-to-male (FTM) transition.
The increased awareness about available options for sex reassignment treatment, supportive governmental regulations for the LGBTQ community, and the emergence of novel hormonal therapies with enhanced efficacy are expected to drive the growth of the U. S. market for sex reassignment hormone therapy. However, it is crucial to consider potential obstacles that may impede market growth, such as legal challenges surrounding the off-label use of sex reassignment drugs and the absence of a well-defined regulatory & reimbursement landscape for these medications.
Major market players such as Viatris Inc.; AbbVie Inc.; ASCEND Therapeutics US, LLC.; Pfizer Inc.; Novartis AG; and Halozyme Therapeutics, Inc. are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in June 2022, Halozyme Therapeutics, Inc. announced the launch of TLANDO, an oral treatment for testosterone therapy. Similarly, Pfizer Inc. announced in June 2023 that DUAVEE (conjugated estrogens) is back in stock in the U. S., featuring improved packaging, following a voluntary recall. The company clarified that the recall was solely related to packaging concerns and did not stem from any efficacy or safety issues with the product.
Hormone therapy is a more economical solution than surgical procedures in gender-affirming care. While it offers a cost-effective solution, it necessitates long-term commitment and consistent usage to achieve desired outcomes. Moreover, in gender-affirming care, several drugs employed in the process are prescribed off-label in the U. S. Puberty blockers serve as the initial line of intervention for individuals seeking sex reassignment, followed by the administration of estrogen or testosterone depending on whether it is a male-to-female (MTF) or female-to-male (FTM) transition.
The increased awareness about available options for sex reassignment treatment, supportive governmental regulations for the LGBTQ community, and the emergence of novel hormonal therapies with enhanced efficacy are expected to drive the growth of the U. S. market for sex reassignment hormone therapy. However, it is crucial to consider potential obstacles that may impede market growth, such as legal challenges surrounding the off-label use of sex reassignment drugs and the absence of a well-defined regulatory & reimbursement landscape for these medications.
Major market players such as Viatris Inc.; AbbVie Inc.; ASCEND Therapeutics US, LLC.; Pfizer Inc.; Novartis AG; and Halozyme Therapeutics, Inc. are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in June 2022, Halozyme Therapeutics, Inc. announced the launch of TLANDO, an oral treatment for testosterone therapy. Similarly, Pfizer Inc. announced in June 2023 that DUAVEE (conjugated estrogens) is back in stock in the U. S., featuring improved packaging, following a voluntary recall. The company clarified that the recall was solely related to packaging concerns and did not stem from any efficacy or safety issues with the product.
U. S. Sex Reassignment Hormone Therapy Market Report Highlights
- Based on gender transition, the male-to-female segment dominated the industry in 2022. This dominance is attributed to increasing treatment awareness and high transwomen population in the country
- Based on type, the estrogen segment held the largest revenue share in 2022. The segment growth is attributed to the availability of a wide range of compatible products and rising demand for male-to-female treatment procedures
- Based on the distribution channel, the retail pharmacies segment dominated the industry in 2022. This is attributed to the better compatibility of retail pharmacies with patients
- Some of the major market players are Viatris Inc.; AbbVie Inc.; ASCEND Therapeutics US, LLC.; Pfizer Inc.; Novartis AG; Lilly (Eli Lilly); and Endo International plc
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Sex Reassignment Hormone Therapy Market Variables, Trends & Scope
Chapter 4. U.S. Sex Reassignment Hormone Therapy Market: Gender Transition Estimates & Trend Analysis
Chapter 5. U.S. Sex Reassignment Hormone Therapy Market: Type Estimates & Trend Analysis
Chapter 6. U.S. Sex Reassignment Hormone Therapy Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Viatris Inc.
- AbbVie Inc.
- ASCEND Therapeutics US, LLC.
- Pfizer Inc.
- Lilly (Eli Lilly)
- Novartis AG
- Endo International plc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1.6 Billion |
| Forecasted Market Value ( USD | $ 2.23 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 7 |
